Physician profile
Mitchell Brady
NPI 1356072789
$5,252.20
in general payments reported to CMS, 2019-2025
21 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $482 · 2023: $1,605 · 2024: $1,477 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,620 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,619.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $841.97 | 2022-2025 | Rinvoq, Skyrizi |
| Dermavant Sciences, INC. | $536.06 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $487.33 | 2023-2025 | Sotyktu |
| Ucb, INC. | $426.81 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $400.28 | 2023-2025 | Tremfya |
| Lilly USA, LLC | $365.36 | 2023-2025 | Olumiant, Ebglyss, Taltz |
| Regeneron Healthcare Solutions, INC. | $354.53 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $305.03 | 2022-2025 | Winlevi |
| Leo Pharma INC. | $278.41 | 2025 | Anzupgo, Spevigo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.25 | 2023-2024 | Spevigo |
| Incyte Corporation | $183.10 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $142.30 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $137.97 | 2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $121.07 | 2022 | |
| Biofrontera INC. | $120.44 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $118.22 | 2024 | Vyjuvek |
| Novartis Pharmaceuticals Corporation | $95.27 | 2024-2025 | |
| Genzyme Corporation | $92.01 | 2023-2025 | |
| Hydrofera LLC | $28.42 | 2022-2023 | Hydrofera Blue |
| Lnhc, INC | $21.60 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $8.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.